TABLE 2.
Univariable and multivariable analysis of risk factors for moxifloxacin resistance by MIC at 0.5 and 2.0 μg/mL in 2013a
| Characteristic | All cases, n | Resistant at 0.5 μg /mL moxifloxacin |
Resistant at 2.0 μg /mL moxifloxacin |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistant, n (%) | Susceptible, n (%) | cPR |
aPR (95% CI) |
cPR |
aPR (95% CI) |
||||||||
| Value | P value | Value | P value | Resistant, n (%) | Susceptible, n (%) | Value | P value | Value | P value | ||||
| Sex | |||||||||||||
| Male | 254 | 100 (39.4) | 154 (60.6) | 1 | 55 (21.7) | 199 (78.3) | 1 | ||||||
| Female | 84 | 40 (47.6) | 44 (52.4) | 1.21 | 0.17 | — | 24 (28.6) | 60 (71.4) | 1.32 | 0.19 | — | ||
| Age (yrs) | |||||||||||||
| <40 | 125 | 48 (38.4) | 77 (61.6) | 1 | 1 | 31 (24.8) | 94 (61.6) | 1 | |||||
| 40 to 59 | 134 | 51 (38.1) | 83 (61.9) | 0.99 | 0.96 | 1.00 (0.74 to 1.36) | 0.99 | 29 (21.6) | 105 (61.9) | 0.87 | 0.55 | — | |
| ≥60 | 79 | 41 (51.9) | 38 (48.1) | 1.35 | 0.06 | 1.46 (1.10 to 1.93) | 0.009 | 19 (24.1) | 60 (48.1) | 0.97 | 0.90 | — | |
| Region of residence within China | |||||||||||||
| Central | 138 | 42 (30.4) | 96 (69.6) | 1 | 1 | 21 (15.2) | 117 (84.8) | 1 | 1 | ||||
| East | 141 | 76 (53.9) | 65 (46.1) | 1.77 | <0.001 | 1.85 (1.38 to 2.48) | <0.001 | 46 (32.6) | 95 (67.4) | 2.14 | 0.001 | 2.14 (1.35 to 3.40) | 0.001 |
| West | 59 | 22 (37.3) | 37 (62.7) | 1.23 | 0.34 | 1.31 (0.88 to 1.96) | 0.18 | 12 (20.3) | 47 (79.7) | 1.34 | 0.38 | 1.34 (0.70 to 2.54) | 0.38 |
| Occupation | |||||||||||||
| Farmer | 209 | 84 (40.2) | 169 (59.8) | 1 | 43 (20.6 | 166 (79.4) | 1 | ||||||
| Other | 129 | 56 (43.4) | 109 (56.6) | 1.08 | 0.56 | — | 36 (43.4) | 93 (72.1) | 1.36 | 0.12 | — | ||
| Number of previous antituberculosis treatments | |||||||||||||
| 0 | 197 | 78 (39.6) | 119 (60.4) | 1 | 50 (25.4) | 147 (74.6) | 1 | ||||||
| 1 | 105 | 46 (43.8) | 59 (56.2) | 1.11 | 0.48 | — | 22 (21.0) | 83 (79.0) | 0.83 | 0.40 | — | ||
| >1 | 36 | 16 (44.4) | 20 (55.6) | 1.12 | 0.58 | — | 7 (19.4) | 29 (80.6) | 0.77 | 0.46 | — | ||
| Previous fluoroquinolone usage for antituberculosis treatment | |||||||||||||
| No | 331 | 137 (41.4) | 194 (58.6) | 1 | 77 (23.3) | 254 (76.7) | 1 | ||||||
| Yes | 7 | 3 (42.9) | 4 (57.1) | 1.04 | 0.94 | — | 2 (28.6) | 5 (71.4) | 1.23 | 0.73 | — | ||
acPR, crude prevalence ratio; aPR, adjust prevalence ratio; CI, confidence interval; “—” , these variables were not included in the final model.